Amendment to Transition and Separation Agreement between Aimmune Therapeutics, Inc. and Stephen G. Dilly
Aimmune Therapeutics, Inc. and Stephen G. Dilly have agreed to extend Dr. Dilly's part-time employment as Special Advisor from the original end date of December 31, 2019, to June 30, 2020. Dr. Dilly will continue to receive his current base salary of $12,000 per year, and his equity awards will keep vesting as before. All other terms of the original Transition and Separation Agreement remain unchanged.
Exhibit 10.1
Aimmune Therapeutics, Inc.
8000 Marina Boulevard, Suite 300
Brisbane, CA 94005
December 19, 2019
Stephen G. Dilly, M.B.B.S., Ph.D.
8000 Marina Boulevard, Suite 300
Brisbane, California 94005
Dear Stephen:
As we have discussed, we are excited to offer you an extension to the term of your employment with Aimmune Therapeutics, Inc. (the Company) on the terms described in this letter. As you know, on November 5, 2017, you and the Company entered into a Transition and Separation Agreement that was amended in December 2018 and June 2019 (as so amended, the Agreement) under which you are employed as Special Advisor to the Company. Under the Agreement, as amended, your part-time employment with the Company is scheduled to end on December 31, 2019 (the Employment End Date). However, as we have discussed, we would like to extend the Planned Resignation Date to June 30, 2020. If you accept this extension, your current base salary will remain $12,000 per annum (your Existing Salary) and your outstanding equity awards continue to vest in accordance with their original terms.
If you are in agreement with the extension described in this letter, please indicate your acceptance of the terms of this letter by your signature below, and return it to me at your earliest convenience. Upon your signature to this letter, the Agreement will be deemed amended to reflect a Planned Resignation Date of June 30, 2020. All other terms and conditions of the Agreement will not be affected by this letter.
Sincerely,
AIMMUNE THERAPEUTICS, INC. | ||
By: | /s/ Douglas T. Sheehy | |
Douglas T. Sheehy | ||
General Counsel & Secretary |
Accepted and Agreed: |
/s/ Stephen G. Dilly |
Stephen G. Dilly, M.B.B.S., Ph.D. |
Date: 12/19/2019 |